definiens: ), the Field shall be expanded to mean ( i ) any and all indications involving the treatment or prevention of picornavirus infecti ons ( including, without limitation, the common cold and LTI ), and ( ii ) any Other Indication s ( as defined in the SaSy Agreement ) to which [COMPANY] obtains rights pursuant to the SaS y Agreement ( the ), and all references in the License Agreement to the shall thereafter mean the Expanded Field ; provided that Schering ’s rights shall be sub ject to Section 2.4(c ) . In such event, on or immediately after the Notice Date, [COMPANY] shall discontinue all efforts to develop and/or commercialize the Compound and/or Products in the E xpanded Field and terminate any disc ussions or interactions with third parties with reg ard to possible licenses or other business transactions related thereto ; provided, however, th at [COMPANY] ’s compassionate use programs for the Compound and/or Products shall be governed by and subject to Section A-3.3